The endocannabinoid system is a neuroactive lipid signaling system that functions to gate synaptic transmitter release. Accumulating evidence has demonstrated that this system is responsive to modulation by both stress and glucocorticoids within the hypothalamus and limbic structures; however, the nature of this regulation is more complex than initially assumed. The aim of the current review is to summarize the research to date which examines the effects of acute stress and glucocorticoid administration on endocannabinoid signaling in limbic-hypothalamic-pituitary-adrenal (LHPA) axis, and in turn the role endocannabinoid signaling plays in the neurobehavioural responses to acute stress and glucocorticoid administration. The majority of research suggests that acute stress produces a mobilization of the endocannabinoid 2-arachidonoylglycerol (2-AG) while concurrently reducing the tissue content of the other endocannabinoid ligand anandamide. Genetic and pharmacological studies demonstrate that the reduction in anandamide signaling may be involved in the initiation of HPA axis activation and the generation of changes in emotional behaviour, while the increase in 2-AG signaling may be involved in terminating the stress response, limiting neuronal activation and contributing to changes in motivated behaviours. Collectively, these studies reveal a complex interplay between endocannabinoids and the HPA axis, and further identify endocannabinoid signaling as a critical regulator of the stress response.
The endocannabinoid system
The endocannabinoid system was first characterized as the neuronal system to which the psychoactive constituent of cannabis, delta-9-tetrahydrocannabinol (THC), interacted to exert its effects on physiology and behaviour. The endocannabinoid system is a unique system, exerting modulatory actions in both central tissue and in the periphery. In the brain, endocannabinoids are generated "on demand" and act retrogradely to regulate the release of neurotransmitters. At the signaling level, two cannabinoid receptors have been characterized to date (Howlett, 2002) . The cannabinoid CB 1 receptor is the receptor that is expressed ubiquitously throughout most regions of the brain (Herkenham et al., 1991; Moldrich and Wenger, 2000; Tsou et al., 1998) ; however, the CB 1 receptor is also known to exhibit some expression patterns in the peripheral tissue, such as immune cells, vascular tissue and adipocytes (Cota et al., 2003; Hillard, 2000; Parolaro, 1999) . While the CB 2 receptor is located predominantly in peripheral immune cells and organs (Munro et al., 1993) , CB2 receptors are also expressed by microglial cells in injured, infected or inflamed CNS tissue (Benito et al., 2008) . There is also recent evidence that cannabinoid CB 2 receptors exhibit limited neuronal expression (Van Sickle et al., 2005) and are present in neural progenitor cells within the hippocampus (Palazuelos et al., 2006) .
Both CB 1 and CB 2 receptors are G-protein coupled receptors. The CB 1 receptor couples to both G i/o proteins which function to inhibit adenylyl cyclase activity, activate potassium channels and inhibit voltage-gated calcium channels, while the CB 2 receptor is only known to couple to G i proteins (Howlett, 2002) . The CB 1 receptor appears to be located predominantly on presynaptic axon terminals, and is capable of regulating calcium influx, and hence neurotransmitter release. Evidence shows that the endocannabinoid system has the ability to inhibit glutamate, GABA, acetylcholine, serotonin and norepinephrine release (Freund et al., 2003; Schlicker and Kathmann, 2001) .
The endogenous ligands for cannabinoid receptors are the arachidonate derived lipophilic molecules N-arachidonylethanolamine (anandamide; AEA (Devane et al., 1992) ) and 2-arachidonylglycerol (2-AG 
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